California Hangs On To Its Biotech Crown, But Other States Are Luring Some Jobs
This article was originally published in The Pink Sheet Daily
Executive Summary
Should I stay or should I go? A new survey suggests many top execs think manufacturing and R&D are better off out-of-state.
You may also be interested in...
Roche Wins Genentech, But Will Biotech Employees Remain?
With a sweetened bid, the Swiss pharma gains the blessing of Genentech’s special committee, but whether the innovator’s valuable staffers sanction the union is an open question.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.